In the Phase I dose escalation portion, which evaluated the combination in participants with small cell lung cancer, the first patient treated attained partial remission.

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, looks back to 2024 and discusses some of the industry’s ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

End-to-end offering is designed to streamline site activation and optimize visibility in critical research processes.

Use of decentralized approach in a Phase 1 pharmacokinetic trial shows the ability to enable remote data collection and ...

Investigators find that most exclusion criteria in critical care randomized clinical trials are justifiable, but 60% include ...

“The goal is to develop life-saving medications for patients faster. That comes down to saving time and money,” said Bonne ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, discusses challenges such as high costs and long ...

In this video interview, Dipanwita Das, CEO & co-founder at Sorcero, highlights how artificial intelligence, real-time monitoring, and historical data can aid in optimizing trial design.

In this video interview, Kimberly Tableman, founder & CEO, ESPERO, discusses how EDC and EHR data can be streamlined to ...

Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a ...

Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical ...